Skip to main content
. 2014 Jul 22;42(14):9399–9409. doi: 10.1093/nar/gku632

Figure 7.

Figure 7.

(A) RdRp activity of HCV-NS5BΔ21 mutants relative to wild type in a cell-free enzyme assay. (B) Susceptibilities of the D559A and F162Y HCV-NS5BΔ21 RdRp mutants to quercetagetin relative to wild type in a cell-free enzyme assay. (C) Fold-increase in IC50s relative to wild type of mutants harboring the P495L, M423T, H95Q, M414T, S556A, C316Y, S96A and S282T substitutions, known to confer resistance to other NNI classes. Benzimidazole, a thumb-1 inhibitor, was used as a control. The mean ± SD of three independent experiments performed in duplicate is shown.